

DIVI'S LABORATORIES LIMITED
Hyderabad

PRESS RELEASE dated 8th November, 2013


Divi's Labs earns a PAT of Rs.205 crores in Q2 of FY14

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.205 crores on a total income of Rs.567 crores, on a stand-alone basis, for the quarter ended 30th September, 2013. For the corresponding quarter of the last year, the company earned a PAT of Rs.118 crores on a total income of Rs. 474 crores.

Forex gain for the current quarter amounted to Rs.31 crores as against a loss of Rs.21 crores during the corresponding quarter of last year.

For the half year ended 30th September, 2013, the company earned a total income of Rs.1084 crores as compared to an income of Rs. 943 crores during the previous half-year. PAT for the current half-year came to Rs. 380 crores as against Rs. 285 crores for the previous half-year.

The company has capitalized fixed assets aggregating to Rs.120 crores during the current half-year.



DIVI'S LABORATORIES LIMITED

UNAUDITED FINANCIAL RESULTS (STANDALONE)
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2013

(₹. in Lakhs)


Sl No.	Particulars	STANDALONE					
		Unaudited					Audited
		Quarter ended			Half Year ended		Year Ended
	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	Income from operations						
	(a) Net Sales/Income from operations (Net of Excise Duty)	56588	51588	47260	108176	94101	212395
	(b) Other Operating Income	107	127	114	234	224	494
	Total Income from operations (net)	56695	51715	47374	108410	94325	212889
2	Expenses						
	a. Cost of materials consumed	28149	28389	23131	56538	40388	89790
	b. Purchases of stock-in-trade		0	0		0	9
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(10133)	(10640)	(6978)	(20773)	(8152)	(10033)
	d. Employee benefits expense	5615	5303	4337	10918	9182	19120
	e. Depreciation and amortization expense	2252	2088	1879	4340	3627	7690
	f. Other Expenses	8192	8945	10385	17137	15176	31828
	Total Expenses	34075	34085	32754	68160	60221	138404
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	22620	17630	14620	40250	34104	74485
4	Other Income	3654	5342	847	8996	2835	4851
5	Profit from ordinary activities before finance costs & exceptional Items (3+4)	26274	22972	15467	49246	36939	79336
6	Finance Costs	39	41	31	80	72	178
7	Profit from ordinary activities after finance costs but before exceptional Items (5-6)	26235	22931	15436	49166	36867	79158
8	Exceptional items	0	0	0	0	0	0
9	Profit from ordinary activities before Tax (7-8)	26235	22931	15436	49166	36867	79158
10	Tax Expense	5742	5460	3639	11202	8332	18016
11	Net Profit from ordinary activities after Tax (9-10)	20493	17471	11797	37964	28535	61142
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0



13	Net Profit (+)/Loss(-) for the period (11-12)	20493	17471	11797	37964	28535	61142
14	Share of profit / (loss) of associates	0	0	0	0	0	0
15	Minority Interest	0	0	0	0	0	0
16	Net Profit (+)/Loss(-) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)	20493	17471	11797	37964	28535	61142
17	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	2655	2655	2655	2655	2655	2655
18	Reserves excluding revaluation reserves as per balance sheet of previous accounting year						252673
19.i	Earnings per Share (before extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	15.44	13.16	8.89	28.60	21.50	46.06
	b) Diluted	15.44	13.16	8.89	28.60	21.50	46.06
19.ii	Earnings per Share (after extraordinary items) (of Rs.2/- each) (not annualized):						
	a) Basic	15.44	13.16	8.89	28.60	21.50	46.06
	b) Diluted	15.44	13.16	8.89	28.60	21.50	46.06

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding - No. of shares - Percentage of shareholding	63512190 47.85%	63512190 47.85%	63512190 47.85%	63512190 47.85%	63512190 47.85%	63512190 47.85%
2	Promoters and promoter group shareholding a) pledged / encumbered b) non-encumbered: - No. of shares - Percentage of shares (as a % of the total shareholding of the promoter group) - Percentage of shares (as a % of the total share capital of the company)	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%	Nil 69222100 100% 52.15%

	Particulars	Quarter ended 30-09-2013
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	7
	Disposed off during the quarter	7
	Remaining unresolved at the end of the quarter	Nil




Statement of Assets and Liabilities:

(₹. in lakhs)

	Particulars	STANDALONE	
		As At	
		30.09.2013	31.03.2013
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	a) Share Capital	2655	2655
	b) Reserves and Surplus	290637	252673
	c) Money received against share warrants	0	0
	Sub-total – Shareholders' funds	293292	255328
2	Share application money pending allotment	0	0
3	Minority interest	0	0
4	Non-current liabilities		
	a) Long-term borrowings	210	210
	b) Deferred tax liabilities (net)	10079	8655
	c) Other long-term liabilities	0	0
	d) Long-term provisions	269	239
	Sub-total – Non-current liabilities	10558	9104
5	Current Liabilities		
	a) Short-term borrowings	3257	3051
	b) Trade payables	20040	15831
	c) Other current liabilities	11855	12935
	d) Short-term provisions	73	23342
	Sub-total – Current liabilities	35225	55159
	TOTAL - EQUITY AND LIABILITIES	339075	319591
B	ASSETS		
1	Non-current assets		
	a) Fixed assets	131594	121191
	b) Goodwill on consolidation	0	0
	c) Non-current investments	282	282
	d) Deferred tax assets (net)	0	0
	e) Long-term loans and advances	10023	10727
	f) Other non-current assets	0	0
	Sub-total – Non-current assets	141899	132200
2	Current assets		
	a) Current investments	31223	40781
	b) Inventories	100004	80595
	c) Trade receivables	55875	55890
	d) Cash and cash equivalents	2818	3468
	e) Short-term loans and advances	6603	5989
	f) Other current assets	653	668
	Sub-total – Current assets	197176	187391
	TOTAL - ASSETS	339075	319591

NOTES:

1. The above results for the quarter ended 30th September 2013, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 8th November, 2013 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
4. Details of forex gain/loss are given below:

	Quarter ended			Half Year ended		Year Ended
	30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013
Forex gain/(loss)	3123	4253	(2078)	7376	926	1516

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

5. Figures for the previous year/period have been regrouped or recasted, wherever necessary.

for Divi's Laboratories Limited

(Signature)
Dr. Murali K. Divi
Chairman & Managing Director



Place: Hyderabad
Date: 8th November, 2013